MIRA INFORM REPORT

 

 

Report Date :

30.09.2011

 

 

 

Tel. No.:

20 2 2877791

Fax No.:

20 2 2877791

 

IDENTIFICATION DETAILS

 

Name :

DELTA PHARMACEUTICAL INDUSTRIES

 

 

Registered Office :

36 Makkram Ebeid Street Nasr City Cairo

 

 

Country :

Egypt

 

 

Financials (as on) :

31.12.2010

 

 

Year of Establishment :

May 1997

 

 

Legal Form :

Egyptian Joint Stock Company

 

 

Line of Business :

Manufacture of therapeutic and diagnostic blood derivatives, plasma substitutes and medical laboratories requisites and pharmaceuticals.

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 400,000

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31st, 2011

 

Country Name

Previous Rating

(31.12.2010)

Current Rating

(31.03.2011)

Egypt

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

 

 

 

SUMMARY

 

Company Name                         : DELTA PHARMACEUTICAL INDUSTRIES

Trading As                                             : DELTA PHARMA COMPANY

Country of Origin                                    : Egypt

Legal Form                                            : Egyptian Joint Stock Company

Registration Date                                   : May 1997

Commercial Registration Number            : 2930348, Cairo

Issued Capital                                        : £E 12,000,000

Paid up Capital                                      : £E 12,000,000

Total Workforce                                     : 600

Activities                                               : Manufacture of therapeutic and diagnostic blood derivatives, plasma

                                                              substitutes and medical laboratories requisites and pharmaceuticals.

Financial Condition                                 : Fair

Payments                                             : Nothing detrimental uncovered

Operating Trend                         : Steady

Recommended Credit Limit                     : US$ 400,000

 

 

 

COMPANY NAME

 

DELTA PHARMACEUTICAL INDUSTRIES

 

TRADING AS: DELTA PHARMA COMPANY

 

 

ADDRESS

 

Registered & Physical Address

 

Street               : 36 Makkram Ebeid Street

Area                 : Nasr City

 

Town                 : Cairo

Country             : Egypt

 

Telephone         : (20-2) 22877791 / 22877792 / 22877793

Facsimile          : (20-2) 22877794

Email                : info@deltapharmaegypt.com

 

Premises

 

Subject operates from a medium sized suite of offices that are rented and located in the Central Business Area of Cairo.

 

Branch Office (s)

 

     Location                                                                                           Description

 

·       Industrial Zone B4, Area No. 77/B                                                       Factory premises

Sharkeya

     PO Box: 1121

     Tenth of Ramadan City

     Tel: (20-15) 373781 / 373782

     Fax: (20-15) 373783

 

·       24 El Glaa Street                                                                              Sales office

Alexandria

     Tel: (20-3) 5760329

 

·       26 July Street                                                                                   Sales office

     Ibn Sina

     Assuit

     Tel: (20-88) 339311

 

 

KEY PRINCIPALS

 

     Name                                                                                               Position

 

·       Dr Mohy Mohamed Hafiz                                                                    Chairman

 

·       Dr Mohamed Tawfik El Rakhawy                                                         Director

 

·       Dr Raouf Hakim Elias                                                                        Director

 

·       Bassel Raouf Hakim                                                                          Director

 

·       Dr Ahmed Abouel Azayem                                                                 Director

 

·       Dr Fayez Shafik                                                                                General Manager

 

·       Dr Mohamed Abbas                                                                           Commercial Manager

 

·       Ahmed Abdallah Eissa                                                                      Finance Manager

 

·       Dr Mamdouh Ali Hassan                                                                    Factory Manager

 

·       Hajaj Hussain                                                                                   Human Resources Manager

 

 

LEGAL FORM & OWNERS

 

Date of Establishment  : May 1997

 

Legal Form                  : Egyptian Joint Stock Company

 

Commercial Reg. No.  : 2930348, Cairo

 

Issued Capital              : £E 12,000,000

 

Paid up Capital            : £E 12,000,000

 

Name of Shareholder (s)

 

·       Dr Mohy Mohamed Hafiz

 

·       Dr Mohamed Tawfik El Rakhawy

 

·       Dr Raouf Hakim Elias

 

·       Bassel Raouf Hakim

 

·       Dr Ahmed Abouel Azayem

OPERATIONS

 

Activities: Engaged in the manufacture of therapeutic and diagnostic blood derivatives, plasma substitutes and

     medical laboratories requisites and pharmaceuticals.

 

Import Countries: Germany, Japan and India

Brand Names: DELTA PHARMA

 

Operating Trend: Steady

 

Subject has a workforce of approximately 600 employees.

 

 

FINANCIAL DATA

 

Financial highlights provided by local sources are given below:

 

Currency: Egyptian Pounds (£E)

 

                                                Year Ending 31/12/09:                Year Ending 31/12/10:

 

Total Sales                                £E 50,655,480                           £E 67,000,480

 

Local sources consider subject’s financial condition to be Fair.

 

The above financial figures are based on estimations by our local sources.

 

 

BANKERS

 

·       National Bank of Egypt

Sharkeya Branch

Tenth of Ramadan City

Tel: (20-15) 360833 / 360744 / 344144

 

·       Cairo Far East Bank SAE

PO Box: 757

Cairo

Tel: (20-2) 33713554 / 33710280

Fax: (20-2) 33483818

 

·       National Bank of Abu Dhabi

Nile Tower, 18th Floor

21 Giza Street

Cairo

Tel: (20-2) 33609724

 

·       Misr International Bank (MIBANK)

14 Alfy Street

     PO Box: 631

     Cairo

     Tel: (20-2) 25931002

     Fax: (20-2) 25912306

 

 

PAYMENT HISTORY

 

No complaints regarding subject’s payments have been reported.

 

Date of transaction                              December 2004                        December 2008

Credit amount                                        100,000                         100,000

Amount overdue                         0                                              0

Payment terms                                      60 days                                     60 days

Payment Method                                   Letters of Credit                         Letters of Credit

Paying record                                        No Complaints                           No Complaints

Currency                                               US Dollars                                 US Dollars

 

 

GENERAL COMMENTS

 

Delta Pharmaceutical Industries was established in 1997 and is engaged in the manufacture of therapeutic and diagnostic blood derivatives, plasma substitutes and medical laboratories requisites, as well as pharmaceuticals.

 

During the course of this investigation nothing detrimental was uncovered regarding subject’s operating history or the manner in which payments are fulfilled. As such the company is considered to be a fair trade risk and the above credit figure is admissible.

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.48.92

UK Pound

1

Rs.76.52

Euro

1

Rs.66.64

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.